All In Biotech

Drug Trial Radar · NCT06434792

Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Dose-response Phase 2 Clinical Trial to Compare the Efficacy and Safety of Bronpass Tab. Versus Placebo in Patients With Stable COPD

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

May 18, 2023

Primary completion

Aug 27, 2024

Study completion Aug 27, 2024

Sponsor

Lead sponsor
Hanlim Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
May 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group dose-response phase 2 clinical trial study to evaluate the efficacy and safety of Bronpass Tab. in 96 patients with chronic obstructive pulmonary disease.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Bronpass Tab.Drug

    Twice daily for 12 weeks

  • PlaceboOther

    Twice daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in CAT(COPD Assessment Test) total score at Visit 5Time frame: Time frame: 3 months(Visit 5)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Konkuk University School of Medicine

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.